Almost 40 Years of Tissue Engineering in Russia: Where Are We Now?

被引:0
|
作者
Alpeeva, Elena [1 ]
Sukhanov, Yury [1 ]
Vorotelyak, Ekaterina [1 ]
机构
[1] Russian Acad Sci, Dept Cell Biol, NK Koltzov Inst Dev Biol, Vavilov Str 26, Moscow 119334, Russia
关键词
regenerative medicine; tissue engineering; skin equivalent; wound healing; clinical trials; marketing authorization; legislation; state strategy of development; REGENERATION; EPITHELIUM;
D O I
10.3390/biomedicines8020025
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
This review describes achievements of Russian cell-based regenerative medicine in different periods of time depending on the legislation and politics, and future prospects for its commercialization and wide application with an emphasis on products devised for skin regeneration. The world's experience in tissue engineering began with the development of living skin equivalents, utilizing a biopolymer matrix and cells at the very beginning of the 1980s. During this period, the USSR kept abreast with the times and also conducted studies on skin wound healing, implementing modern cell techniques. However, there soon emerged a gap between scientific advancement and practical application. After the breakup of the USSR, there were no institutions that could implement scientific inventions into full-scale manufacturing for clinical application. At the same time, accumulating scientific and practical experience allowed for the maintenance of biomedical research and its readiness for market entry at present. Recently developed legislation opens up new opportunities in this field in Russia. There are a growing number of studies on the development of novel products for regenerative medicine, bringing hope for its rapid progress.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Ethnic minorities and weight control research priorities: Where are we now and where do we need to be?
    Kumanyika, Shiriki
    PREVENTIVE MEDICINE, 2008, 47 (06) : 583 - 586
  • [32] Creating a wearable artificial kidney: where are we now?
    Kooman, Jeroen P.
    Joles, Jaap A.
    Gerritsen, Karin G. F.
    EXPERT REVIEW OF MEDICAL DEVICES, 2015, 12 (04) : 373 - 376
  • [33] Applicability of pain neuroscience education: Where are we now?
    Barbari, Valerio
    Storari, Lorenzo
    Maselli, Filippo
    Testa, Marco
    JOURNAL OF BACK AND MUSCULOSKELETAL REHABILITATION, 2021, 34 (04) : 511 - 520
  • [34] Chemotherapy-induced peripheral neuropathy: where are we now?
    Colvin, Lesley A.
    PAIN, 2019, 160 : S1 - S10
  • [35] Drug therapy for amyotrophic lateral sclerosis: Where are we now?
    Carter, GT
    Krivickas, LS
    Weydt, P
    Weiss, MD
    Miller, RG
    IDRUGS, 2003, 6 (02) : 147 - 153
  • [36] Motor unit number estimation (MUNE): Where are we now?
    de Carvalho, Mamede
    Barkhaus, Paul E.
    Nandedkar, Sanjeev D.
    Swash, Michael
    CLINICAL NEUROPHYSIOLOGY, 2018, 129 (08) : 1507 - 1516
  • [37] Postmeniscectomy Meniscus Growth With Stem Cells: Where Are We Now?
    McCrum, Christopher L.
    Vangsness, C. Thomas
    SPORTS MEDICINE AND ARTHROSCOPY REVIEW, 2015, 23 (03) : 139 - 142
  • [38] The Levels of Evidence in Pediatric Orthopaedic Journals: Where Are We Now?
    Cashin, Megan S.
    Kelley, Simon P.
    Douziech, Jeffery R.
    Varghese, Renjit A.
    Hamilton, Quinn P.
    Mulpuri, Kishore
    JOURNAL OF PEDIATRIC ORTHOPAEDICS, 2011, 31 (06) : 721 - 725
  • [39] Thirty Years of Tissue Engineering
    Atala, Anthony
    TISSUE ENGINEERING PART A, 2024, 30 (1-2) : 5 - 13
  • [40] An update on stem cell therapy for stroke patients: Where are we now?
    Gordon, Jonah
    Borlongan, Cesar, V
    JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2024, 44 (09) : 1469 - 1479